TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05391659

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: deep learning
Description: a form of artificial intelligence (AI), has been introduced for automated analysis of images

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: remote grading of fundus images
Description: referrable cases identified by DR AI tool will be remotely graded by a human

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: gold standard
Description: examination by ophthalmologist
Study: NCT06393764

Intervention type: OTHER
Intervention: Collection of biological samples
Description: Collecte of blood and urine samples
Study: NCT06080659

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: fMRI
Description: functional MRI

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: fMRI
Description: functional MRI

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: fMRI
Description: functional MRI

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: fMRI
Description: functional MRI

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: fMRI
Description: functional MRI

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CONFMEM
Description: The aim of this paradigm is to identify the impact of cognitive conflict situations on recognition memory (the ability to judge whether or not a stimulus has been previously presented).

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: CONFMEM
Description: The aim of this paradigm is to identify the impact of cognitive conflict situations on recognition memory (the ability to judge whether or not a stimulus has been previously presented).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CONFMEM
Description: The aim of this paradigm is to identify the impact of cognitive conflict situations on recognition memory (the ability to judge whether or not a stimulus has been previously presented).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CONFMEM
Description: The aim of this paradigm is to identify the impact of cognitive conflict situations on recognition memory (the ability to judge whether or not a stimulus has been previously presented).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CONFMEM
Description: The aim of this paradigm is to identify the impact of cognitive conflict situations on recognition memory (the ability to judge whether or not a stimulus has been previously presented).
Study: NCT05021536

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo Comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMX0035
Description: Proprietary formulation of taurursodiol and sodium phenylbutyrate
Study: NCT04692506

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: The study product is probiotic

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: The study product is probiotic

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic
Description: The study product is probiotic
Study: NCT05205837

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole 2.5mg, hCG
Description: Drug -Treatment Intramuscular injektion - Treatment
Study: NCT05954377

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quarterly remote motivational interviews
Description: Remote motivational interview will be in the form of quarterly telephone call (at 3, 6 and 9 months after the start of annual follow up; the patient is seen again at 12 months as part of the annual follow-up) and this for 4 years. It will be performed by medical staff trained in motivational interviewing and who have completed at least 40 hours training in therapeutic education
Study: NCT05460871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 75mg
Description: participants will receive pregabalin orally 75mg twice daily x 7 days prior to surgery, then 150mg twice daily x 7 days after surgery, followed by 75mg twice daily x 7 days, then stop.
Study: NCT05205837

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug - Placebo Intramuscular injektion - placebo
Study: NCT05781308

Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel
Description: Paclitaxel 200 mg/m² every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 200 mg/m² every 3 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Bevacizumab
Description: Bevacizumab 15 mg/kg every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 15 mg/kg every 3 weeks
Study: NCT05196100

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amparo confidence socket
Description: Confidence socket involves thermoplastic material being moulded onto the patient's residual limb and a socket is produced in a single session. The socket can be remoulded to adjust to changes in residual limb volume.
Study: NCT05744700

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Inulinase
Description: Participants will consume one capsule containing 1,000 INU inulinase, twice daily, for 28 days. Participants will be directed to consume the capsules with their two largest meals.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin placebo
Description: Participants will consume one capsule containing maltodextrin, twice daily, for 28 days. Participants will be directed to consume the capsules with their two largest meals.
Study: NCT05716373

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pain
Description: reiki
Study: NCT05288517

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lock to Live
Description: Lock to Live is an anonymous web-based self-administered decision aid for safe firearm and medication storage (Public URL: http://lock2live.com/).
Study: NCT05301556

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Product
Description: * Before the surgery: FSMP provides daily target energy needed by participants~* 1-2 days after surgery: Start FSMP and advance as tolerated to achieve 20% of the daily target energy needed by participants~* 3rd-5th day after surgery: Gradually increase FSMP intake every day as tolerated to provide 30-80% of the daily target energy needed by participants~* 6th to 11th day after surgery. FSMP provides daily target energy needed by participants
Study: NCT05781308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200 mg every 3 weeks
Study: NCT04716634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab is a humanized, immunoglobulin G4 (IgG4)-variant monoclonal antibody against PD 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: Fruquintinib is a potent, oral VEGFR tyrosine kinase inhibitor (TKI)
Study: NCT05130801

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: pHLIP® ICG NIRF imaging
Description: Pre-operative research MRI will be performed 1-3 weeks prior to the surgery. single pHLIP® ICG injection will be administered i.v. by a radiologist on the protocol one day prior to scheduled surgery on the occasion of presurgical localization (12-36 hours prior to the surgery).~In Phase I, we propose to investigate 4 different doses:~Dose level 1 = 0.04 mg/kg Dose level 2 = 0.075 mg/kg Dose level 3 = 0.15 mg/kg Dose level 4 = 0.30 mg/kg~In Phase IIa, the researchers propose to administer selected in Phase I dose of pHLIP® ICG. In Phase IIa, the researchers propose to administer pHLIP® ICG at DL2, DL3 or DL4 at different time points prior to surgery ranging from 12-110 hours, with targeted enrollment of 12 patients. Next, the selected optimal dose and timing will be used with targeted enrollment of 28 patients. The total number of subjects in Phase IIa study is 40.
Study: NCT05844618

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide (Aristocort® C)
Description: On Day 1, Day 2, and Day 3, subjects will receive 2 applications of 3 mg/cm2 on the same lesional area, at an interval of approximately 12 ± 2 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: On Day 1, Day 2, and Day 3, subjects will receive 2 applications of 3 mg/cm2 on the same lesional area, at an interval of approximately 12 ± 2 hours.
Study: NCT05301556

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Product
Description: * Before surgery: TPF-T provides daily target energy needed by participants~* 1-2 days after surgery: Start TPF-T and advance as tolerated to achieve 20% of the daily target energy needed by participants~* 3rd-5th day after surgery: Gradually increase TPF-T intake every day as tolerated to provide 30-80% of the daily target energy needed by participants~* 6th to 11th day after surgery. TPF-T provides daily target energy needed by participants
Study: NCT06484530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N acetyl cysteine
Description: 1,200 mg/day for 8 weeks in NAT2 gene testing group and NAT2 gene phenotype is identified as slow acetylator.
Study: NCT05192070

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Percussive Massage Group
Description: Quadriceps, hamstring and gastrocnemius muscles of the participants will done massage for 3 minutes with a hypervolt massage device.
Study: NCT06523855

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bilateral alveolar cleft grafting using iliac crest particulate and microplate fixation
Description: bilateral alveolar cleft grafting using particulate iliac crest graft accompanied with fixation of graft and premaxilla using microplate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bilateral alveolar cleft grafting using iliac crest particulate and microplate fixation
Description: bilateral alveolar cleft grafting using particulate iliac crest graft accompanied with fixation of graft and premaxilla using microplate
Study: NCT05930158

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual Task Exercises
Description: Cognitive exercises to be added during walking and balance exercises will be given as a dual task. Cognitive exercises will consist of exercises for memory, executive functions, calculation, information processing speed (reaction time) and working memory areas. Cognitive exercises such as grouping the words given, giving appropriate answers to the simple situations described, simple addition, subtraction, multiplication, and asking the words that the patient is asked to remember before the exercise will be used. Cognitive exercises will be performed simultaneously with walking and balance exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation
Description: Pulmonary Rehabilitation content; relaxation exercises, stretching exercises, strengthening exercises, walking exercises, cycling exercises, balance exercises. Exercise intensity will be planned as moderate intensity. Walking and cycling exercises will have warm-up and cool-down periods.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Rehabilitation
Description: Pulmonary Rehabilitation content; relaxation exercises, stretching exercises, strengthening exercises, walking exercises, cycling exercises, balance exercises. Exercise intensity will be planned as moderate intensity. Walking and cycling exercises will have warm-up and cool-down periods.
Study: NCT04919382

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study: NCT05658198

Intervention type: BEHAVIORAL
Intervention: Counseling
Description: Patients who first decline HPV vaccination receive a 3-5 minute counseling session on HPV and the benefits of the vaccine.
Study: NCT06620614

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: 0.5% Heavy Bupivacaine
Description: There are two groups.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 0.5% Heavy Bupivacaine
Description: There are two groups.
Study: NCT06627205

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Restriction Therapy
Description: Therapist led sleep restriction therapy sessions.
Study: NCT06629051

Intervention type: DRUG
Intervention: Berberine Hydrochloride
Description: post-intervention of berberine

Intervention type: DRUG
Intervention: Placebo
Description: Looks the same as berberine
Study: NCT05404230

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil
Description: Fish oil containing poly unsaturated fatty acids.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Corn oil
Description: Corn oil
Study: NCT06386913

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: Measurement-Based Care Training
Study: NCT06390592

Intervention type: DEVICE
Group type: OTHER
Intervention: PD cycler
Description: Patients are treated continuously during Peritoneal dialysis with the PD cycler sleep•safe harmony with different FlexPoint settings.~According to their randomization the patients are treated with Treatment A, B or C in a different order:~* standard (default) FlexPoint settings (Treatment A)~* minimum value FlexPoint settings (Treatment B)~* maximum value for permitted peritoneal residual volume (50%) of FlexPoint settings (Treatment C)
Study: NCT04614584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Description: Mirtazapine 30 mg PO daily x 4 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methamphetamine
Description: Methamphetamine 30 mg IV once

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methamphetamine
Description: Methamphetamine 30 mg IV once
Study: NCT05192070

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic stretching group
Description: Dynamic stretching will be performed for the quadriceps, hamstring and gastrocnemius muscles of the participants with 10 repetitions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static stretching group
Description: Static stretching will be performed for the quadriceps, hamstring and gastrocnemius muscles of the participants with 10 repetitions.
Study: NCT05454358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5mg
Description: Letrozole 0.5mg qd po for 2 years after postoperative adjuvant therapy
Study: NCT06193785

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: hypnosis realised by expert practitioner, before and during the electromyogram procedure
Study: NCT05819450

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Volumetric rejuvenation
Description: Volumetric Rejuvenation with FDA-approved fillers on the skin of the dorsal hands
Study: NCT06571864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-CD38 Monoclonal Antibody
Description: Anti-CD38 Monoclonal Antibody: Daratumumab is intravenously given at the dose of 16 mg/kg weekly for 8 weeks, then every two weeks for 8 more times, and lastly monthly until the 52nd week (8 more administrations)
Study: NCT06230913

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesiotape
Description: To perform taping of the chest, the patient was asked to stand upright with the affected shoulder rotated externally. Five straps of the fan shaped tape were extended to the chest toward the affected axilla with 15% to 20% tension, and the anchor was positioned without tension in the anterior axilla on the sound side.
Study: NCT04890964

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: A stimulation device, that releases 2.0mA current by a 35 cm2 electrode direct located on a specific location on the scalp for 20 minutes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: A stimulation device, that releases 2.0mA current by a 35 cm2 electrode direct located on a specific location on the scalp for 20 minutes

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: A stimulation device, that releases 2.0mA current by a 35 cm2 electrode direct located on a specific location on the scalp for 20 minutes

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: A stimulation device, that releases 2.0mA current by a 35 cm2 electrode direct located on a specific location on the scalp for 20 minutes
Study: NCT06466005

Intervention type: OTHER
Intervention: UnityPhilly app
Description: UnityPhilly automatically connects bystanders and victims of opioid overdose with nearby community members who can respond immediately with naloxone.

Intervention type: OTHER
Intervention: UnityPhilly app
Description: UnityPhilly automatically connects bystanders and victims of opioid overdose with nearby community members who can respond immediately with naloxone.
Study: NCT06230913

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pressure garment
Description: The skin was washed and dried before applying the PG. The Premium Lymphedema Gradient Garment (Jobskin, Long Eaton, England) was used to apply PGs. This garment has a pressure gradient built into it, applying between 20 and 60 mm Hg for at least 15 to 18 hours each day for three weeks. The gradient counter pressure is applied using a gram tension.
Study: NCT06267846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-1070770
Description: Suspension for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-1070770
Description: Suspension for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-1070770
Description: Suspension for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Suspension for oral administration
Study: NCT05704088

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin tablet
Description: randomized control trial, study group will receive dapagliflozin tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: randomized control trial, control group will receive placebo tablets
Study: NCT04714177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edaravone Dexborneol
Description: Edaravone Dexborneol 37.5 mg, containing Edaravone 30 mg and Dexborneol 7.5 mg, Edaravone Dexborneol 37.5 mg BID, 14 days, addition to standard of care of Intracerebral Hemorrhage

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Edaravone Dexborneol matching injection, addition to standard of care of Intracerebral Hemorrhage
Study: NCT06165731

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diaphragmatic Breathing Exercises
Description: Mindful deep breathing cycle comprised of a 3-second inhale causing abdominal wall movement followed by a 5-second exhale, which will be completed for a total of 10 minutes of daily exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bladder Hygiene Education
Description: Educational handout on bladder health and hygiene with recommendations endorsed by the International Urogynecologic Association

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bladder Hygiene Education
Description: Educational handout on bladder health and hygiene with recommendations endorsed by the International Urogynecologic Association
Study: NCT05283460

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mandala
Description: The Life Satisfaction Scale was administered to patients in the control group at the first encounter (pre-test) and three weeks after the first encounter (post-test). Although the pre- and post-test treatment protocols were the same for both intervention and control groups, the only difference between their treament was the mandala activity, which was not applied to those in the control group. Patients in the control group continued their routine lives at home for three weeks. After the application, the mandala activity was applied to all patients who wanted it.
Study: NCT06353958

Intervention type: DRUG
Intervention: MiSaver
Description: MiSaver vials was thawed using a thermostat-controlled mini bath, drawn into a 20ml syringe, and diluted with normal saline and intravenous infused following standard operating procedures, consecutively, until reasching the dosage.~Patients were premedicated with intravenous antihistamines (such as diphenhydramine) and corticosteroids (such as hydrocortisone) 30-60 minutes before the stem cell infusion. Any unused solution was discarded, and the total volume of injected solution was adjusted to accommodate the total daily fluid volume administered.

Intervention type: DRUG
Intervention: MiSaver
Description: MiSaver vials was thawed using a thermostat-controlled mini bath, drawn into a 20ml syringe, and diluted with normal saline and intravenous infused following standard operating procedures, consecutively, until reasching the dosage.~Patients were premedicated with intravenous antihistamines (such as diphenhydramine) and corticosteroids (such as hydrocortisone) 30-60 minutes before the stem cell infusion. Any unused solution was discarded, and the total volume of injected solution was adjusted to accommodate the total daily fluid volume administered.
Study: NCT05202028

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reflexology
Description: After the physical therapy applied to the patient by the physiotherapist in the special education center for 8 weeks, 3 days a week for about 15-20 minutes. reflexology will be practiced. To families; Training will be given on sleep hygiene, nutritional recommendations and lifestyle changes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Connective Tissue Massage
Description: After the physical therapy applied to the patient by the physiotherapist in the special education center, 3 days a week for 8 weeks, once a day for approximately 15-20 minutes. Connective tissue massage will be applied. To families; Training will be given on sleep hygiene, nutritional recommendations and lifestyle changes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classic abdominal massage
Description: After the physical therapy applied to the patient by the physiotherapist in the special education center for 8 weeks, 3 days a week for about 15-20 minutes. reflexology will be practiced. To families; Training will be given on sleep hygiene, nutritional recommendations and lifestyle changes.